B. Metzler seel. Sohn & Co. AG Invests $840,000 in Natera, Inc. $NTRA

B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,095 shares of the medical research company's stock, valued at approximately $840,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC grew its stake in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock valued at $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth grew its stake in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock valued at $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Natera in the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd acquired a new position in Natera in the second quarter worth approximately $558,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on NTRA. Barclays reiterated an "overweight" rating and issued a $340.00 target price on shares of Natera in a research note on Friday, August 7th. Wall Street Zen lowered shares of Natera from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. Piper Sandler raised their price target on shares of Natera from $249.00 to $363.50 and gave the company an "overweight" rating in a report on Wednesday, August 12th. BTIG Research lifted their price objective on shares of Natera from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Finally, Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $319.38.

Insider Activity

In other Natera news, CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the transaction, the chief financial officer directly owned 51,637 shares of the company's stock, valued at $14,159,898.14. The trade was a 0.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares of the company's stock, valued at approximately $26,611,561.83. This trade represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 177,955 shares of company stock valued at $40,704,193 over the last three months. 5.05% of the stock is currently owned by insiders.

Natera Stock Performance

NTRA opened at $327.72 on Tuesday. The business has a 50 day moving average price of $276.45 and a 200 day moving average price of $230.09. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $333.56. The firm has a market cap of $47.24 billion, a P/E ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same quarter in the prior year, the business earned ($0.74) earnings per share. The company's revenue was up 37.7% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source